<![CDATA[<body bgcolor="#FFFFFF" text="#000000">
Glenmark Pharmaceuticals formulations business operates in over 65 countries including India. The company employs over 1700 medical reps across these markets; of these over 350 medical representatives and front line managers are employed in markets outside India.
In the semi-regulated markets spanning Asia, Africa, Latin America and Russia/CIS regions, the company has adopted a "Branded generics" model. In contrast the company's business operations in the regulated markets of USA and EU are "Generic" in nature.
Glenmark's formulation business has invested in building a manufacturing footprint to cater to the demand. The current footprint includes:
One WHO-GMP plant at Nasik to cater to semi-regulated markets including India. The plant handles several dosage forms including liquids, solids, semi-solids and dry powders.
A plant at Goa built to USFDA and EU standards and commissioned during March-April 2004. The plant has capabilities to manufacture tablets, capsules and ointments/creams.
One ANVISA approved manufacturing plant in Brazil to cater to Latin American markets. This plant has capabilities in solids, liquids and semi-solids.
In India, the company markets about 100 molecules/combinations spanning a diverse set of therapy segments such as Dermatology, respiratory, gynaecology, pain management, diabetes, cardio-vascular, internal medicine etc. Over 50 of these molecules/combinations are also being marketed across the semi-regulated markets of Asia, Africa, Russia/CIS; several more products are under registration in these markets. The company markets about 24 products in Brazil with several new registrations planned each year starting with 6-8 in FY 2006.
In regulated markets filings commenced in FY 2005 and the company had filed 6 ANDAs in the US by March 2005. In the next few years, the company plans to file over 14 ANDAs per year in the US market. It is also working with several alliance partners to broaden the basket of offerings in the US.
</body>]]>